We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Unveils HemoSphere Stream for Continuous Noninvasive BP Monitoring
Read MoreHide Full Article
Key Takeaways
BDX introduced HemoSphere Stream for continuous, noninvasive BP monitoring.
The module delivers real-time waveform data and integrates easily, reducing the need for invasive route.
The launch supports recurring consumables revenue and aligns with rising demand for data-driven patient care.
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the launch of its HemoSphere Stream Module, a new solution that enables continuous, noninvasive blood pressure monitoring across compatible bedside monitors.
From an investor standpoint, the launch reinforces BD’s focus on innovation within its Advanced Patient Monitoring portfolio, a key growth area driven by rising demand for safer, data-driven care. The ability to integrate with existing multiparameter monitors lowers adoption friction, while alignment with clinical recommendations for continuous monitoring could support faster uptake.
Likely Trend of BDX Stock Following the News
Shares of BDX have traded flat since the announcement on Tuesday. In the year-to-date period, shares of the company lost 20.2% compared with the industry’s 3.3% decline and the S&P 500’s 3.6% fall.
The HemoSphere Stream launch can support BD’s long-term growth by expanding its reach in advanced patient monitoring and enabling wider adoption through noninvasive, easy-to-integrate solutions. It opens up recurring revenue streams via consumables while strengthening customer stickiness and positioning BD to benefit from the growing demand for continuous, data-driven patient care.
BDX currently has a market capitalization of $44 billion.
Image Source: Zacks Investment Research
More on the Launch
BDX’s HemoSphere Stream Module is designed to deliver continuous, noninvasive blood pressure monitoring by providing real-time, beat-to-beat arterial waveform data through a finger cuff-based system. The module integrates directly with compatible multiparameter patient monitors, allowing clinicians to view continuous hemodynamic data without requiring invasive arterial lines. Compact and easy to deploy, it mounts onto standard IV poles, ensuring minimal disruption to existing clinical workflows. When paired with the VitaWave Plus Finger Cuff and accessories, it forms the VitaWave Plus System, which has been validated for accuracy against traditional arterial line measurements.
Clinically, the solution addresses a key gap associated with intermittent blood pressure checks, which are typically performed every few minutes and may miss critical fluctuations. By enabling continuous monitoring, the system helps clinicians detect and respond to hemodynamic instability, such as intraoperative hypotension, in real time. The launch also aligns with recommendations from the Anesthesia Patient Safety Foundation advocating for continuous, noninvasive monitoring to improve patient outcomes. Overall, the innovation enhances visibility into patient status across a broader range of care settings, supporting safer and more proactive clinical decision-making.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global non-invasive blood pressure monitors market size was calculated at $32.34 billion in 2025 and is predicted to increase from $34.61 billion in 2026 to approximately $63.18 billion by 2035, expanding at a CAGR of 6.93% from 2026 to 2035.
The non-invasive blood pressure monitors market is projected to witness continued growth, driven by the prevalence of hypertension, an aging population and technological advancements.
Other News
BD recently announced the European launch of its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform. The combined offering leverages automation and AI-driven insights to streamline medication workflows, reduce inefficiencies and free up clinician time for patient care.
Per management, these innovations set a new standard for data-driven medication management. By bringing the integrated platform to European hospitals, BD aims to enhance medication availability, improve operational efficiency and support better patient outcomes.
BDX’s Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BD Unveils HemoSphere Stream for Continuous Noninvasive BP Monitoring
Key Takeaways
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the launch of its HemoSphere Stream Module, a new solution that enables continuous, noninvasive blood pressure monitoring across compatible bedside monitors.
From an investor standpoint, the launch reinforces BD’s focus on innovation within its Advanced Patient Monitoring portfolio, a key growth area driven by rising demand for safer, data-driven care. The ability to integrate with existing multiparameter monitors lowers adoption friction, while alignment with clinical recommendations for continuous monitoring could support faster uptake.
Likely Trend of BDX Stock Following the News
Shares of BDX have traded flat since the announcement on Tuesday. In the year-to-date period, shares of the company lost 20.2% compared with the industry’s 3.3% decline and the S&P 500’s 3.6% fall.
The HemoSphere Stream launch can support BD’s long-term growth by expanding its reach in advanced patient monitoring and enabling wider adoption through noninvasive, easy-to-integrate solutions. It opens up recurring revenue streams via consumables while strengthening customer stickiness and positioning BD to benefit from the growing demand for continuous, data-driven patient care.
BDX currently has a market capitalization of $44 billion.
Image Source: Zacks Investment Research
More on the Launch
BDX’s HemoSphere Stream Module is designed to deliver continuous, noninvasive blood pressure monitoring by providing real-time, beat-to-beat arterial waveform data through a finger cuff-based system. The module integrates directly with compatible multiparameter patient monitors, allowing clinicians to view continuous hemodynamic data without requiring invasive arterial lines. Compact and easy to deploy, it mounts onto standard IV poles, ensuring minimal disruption to existing clinical workflows. When paired with the VitaWave Plus Finger Cuff and accessories, it forms the VitaWave Plus System, which has been validated for accuracy against traditional arterial line measurements.
Clinically, the solution addresses a key gap associated with intermittent blood pressure checks, which are typically performed every few minutes and may miss critical fluctuations. By enabling continuous monitoring, the system helps clinicians detect and respond to hemodynamic instability, such as intraoperative hypotension, in real time. The launch also aligns with recommendations from the Anesthesia Patient Safety Foundation advocating for continuous, noninvasive monitoring to improve patient outcomes. Overall, the innovation enhances visibility into patient status across a broader range of care settings, supporting safer and more proactive clinical decision-making.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global non-invasive blood pressure monitors market size was calculated at $32.34 billion in 2025 and is predicted to increase from $34.61 billion in 2026 to approximately $63.18 billion by 2035, expanding at a CAGR of 6.93% from 2026 to 2035.
The non-invasive blood pressure monitors market is projected to witness continued growth, driven by the prevalence of hypertension, an aging population and technological advancements.
Other News
BD recently announced the European launch of its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform. The combined offering leverages automation and AI-driven insights to streamline medication workflows, reduce inefficiencies and free up clinician time for patient care.
Per management, these innovations set a new standard for data-driven medication management. By bringing the integrated platform to European hospitals, BD aims to enhance medication availability, improve operational efficiency and support better patient outcomes.
BDX’s Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.